Gsk (GSK) Price to Sales (2026)

Gsk (GSK) has 18 years of Price to Sales data on file, last reported at 1.24 in Q3 2026.

• For the quarter ending Q3 2026, Price to Sales changed N/A year-over-year to 1.24; the trailing twelve-month figure through Sep 2026 stood at 1.24 (changed N/A YoY), and the FY2025 full-year result was 2.44, up 33.87% from the prior year.
• Price to Sales was 1.24 for Q3 2026 at Gsk, down from 1.48 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 2.25 in Q1 2022 to a low of 1.24 in Q3 2026.
• A 5-year average of 1.72 and a median of 1.76 in 2024 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales slumped 58.09% in 2022 and increased 17.96% in 2023, its largest moves.
• Gsk's Price to Sales stood at 1.72 in 2022, then rose by 2.86% to 1.76 in 2023, then dropped by 16.08% to 1.48 in 2024, then fell by 4.85% to 1.41 in 2025, then fell by 11.7% to 1.24 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 1.24 in Q3 2026, 1.48 in Q2 2026, and 1.57 in Q1 2026.